Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. (GLUE): 4 pipeline candidates · ~26 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
25.6 months
D/E 0.41 · 18% dilution
Lead: Phase 1/Phase 2
4 candidates
N/A
0 buys · 23 sells (180d)
A transparent, data-derived signal for Monte Rosa Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.5B
Cash
$164.8M
Quarterly Burn
$37.4M
Runway
25.6 mo
Revenue
$4.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| mrt-2359 | Phase 1/Phase 2 |
| mrt-6160 | Phase 1 |
| mrt-8102 | Phase 1 |
| oral mrt-2359 | Phase 1/Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
187
Total value held
$1.12B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 6,200,490 | $102.0M |
| blackrock, inc. | 5,637,684 | $92.7M |
| bvf inc/il | 4,460,886 | $73.4M |
| baker bros. advisors lp | 4,345,736 | $71.5M |
| suvretta capital management, llc | 4,226,809 | $69.5M |
| state street corp | 3,353,980 | $55.2M |
| braidwell lp | 3,206,574 | $52.7M |
| versant venture management, llc | 3,180,780 | $52.3M |
| american century companies inc | 2,809,647 | $46.2M |
| silverarc capital management, llc | 2,002,040 | $32.9M |
Showing top 10 of 187 institutional holders of Monte Rosa Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Monte Rosa Therapeutics, Inc.'s pipeline?
Monte Rosa Therapeutics, Inc. (GLUE) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Monte Rosa Therapeutics, Inc.'s lead drug candidate?
Monte Rosa Therapeutics, Inc.'s most advanced tracked candidate is mrt-2359 (Phase 1/Phase 2) for NSCLC.
What is Monte Rosa Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Monte Rosa Therapeutics, Inc. has approximately 25.6 months of cash runway.
What is Monte Rosa Therapeutics, Inc.'s market capitalization?
Monte Rosa Therapeutics, Inc.'s market capitalization is approximately $1.5B.
Who is the CEO of Monte Rosa Therapeutics, Inc.?
Dr. Markus Warmuth M.D. is the chief executive officer of Monte Rosa Therapeutics, Inc. (GLUE).
Get the full picture on Monte Rosa Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.